Cantor Fitzgerald L. P. Acquires 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)

Cantor Fitzgerald L. P. increased its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 61.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 539,726 shares of the company's stock after buying an additional 205,534 shares during the quarter. Cantor Fitzgerald L. P. owned about 1.80% of Silence Therapeutics worth $3,713,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. JPMorgan Chase & Co. bought a new stake in shares of Silence Therapeutics during the 4th quarter worth $26,000. Barclays PLC lifted its holdings in shares of Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after purchasing an additional 5,233 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Silence Therapeutics in the 4th quarter worth about $69,000. Finally, Virtus ETF Advisers LLC increased its stake in Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after purchasing an additional 6,098 shares in the last quarter. Institutional investors own 98.73% of the company's stock.

Analyst Ratings Changes

SLN has been the subject of several recent analyst reports. Morgan Stanley decreased their target price on shares of Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research report on Friday, March 7th. The Goldman Sachs Group decreased their price objective on shares of Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a research note on Tuesday, March 4th. Finally, BMO Capital Markets cut their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, Silence Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

Silence Therapeutics Trading Down 0.2 %

SLN stock traded down $0.01 during midday trading on Wednesday, reaching $3.74. The company had a trading volume of 209,152 shares, compared to its average volume of 298,137. The company has a 50 day moving average of $3.42 and a two-hundred day moving average of $6.77. Silence Therapeutics plc has a 1 year low of $1.97 and a 1 year high of $24.38. The company has a market capitalization of $112.06 million, a P/E ratio of -2.38 and a beta of 1.20.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.